21721-92-6
Chemical Structure
Nitrefazole
Synonym(s): EMD-15700
- CAS No.: 21721-92-6
- Formula:C10H8N4O4
- Molecular Weight:248.19
IUPAC Name: 2-methyl-4-nitro-1-(4-nitrophenyl)-1H-imidazole
InChIKey: NMTBSNPBIGRZBL-UHFFFAOYSA-N
SMILES: CC1=NC([N+]([O-])=O)=CN1C2=CC=C([N+]([O-])=O)C=C2
Biological Activity: Nitrefazole (EMD-15700) is an aldehyde dehydrogenase (ALDH) inhibitor. Nitrefazole specifically inhibits human liver ALDH I and human erythrocyte ALDH isozymes, but does not alter the activity of human liver ALDH II or human placental ALDH. Nitrefazole effectively promotes exosome secretion in prostate cancer cells by increasing the levels of Alix, nSMase2, Rab27a and p-ERK. Nitrefazole can be used in studies related to prostate cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nitrefazole | 99.44% | Nitrefazole (EMD-15700) is an aldehyde dehydrogenase (ALDH) inhibitor. Nitrefazole specifically inhibits human liver ALDH I and human erythrocyte ALDH isozymes, but does not alter the activity of human liver ALDH II or human placental ALDH. Nitrefazole effectively promotes exosome secretion in prostate cancer cells by increasing the levels of Alix, nSMase2, Rab27a and p-ERK. Nitrefazole can be used in studies related to prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nitrefazole (Standard) | ≥98% | Nitrefazole (Standard) is the analytical standard of Nitrefazole. This product is intended for research and analytical applications. Nitrefazole is a 4-nitroimidazole derivative with strong and long lasting inhibition of aldehyde dehydrogenase (ALDH), an enzyme involved in the metabolism of alcohol. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Datta A, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Scientific reports. 2018 May 25;8(1):8161. [Content Brief]
- [2]. Joo HS, et al. Current Knowledge and Future Perspectives on Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Agent. International journal of molecular sciences. 2020 Jan 22;21(3):727. [Content Brief]
- [3]. Zorzano A, et al. Differences in the kinetic properties and sensitivity to inhibitors of human placental, erythrocyte, and major hepatic aldehyde dehydrogenase isoenzymes. Biochemical pharmacology. 1990 Mar 01;39(5):873-8. [Content Brief]
Keywords
